ADC Contract Manufacturing Market (3rd Edition), 2018-2030

  • ID: 4658301
  • Report
  • Region: Global
  • 350 Pages
  • Roots Analysis
1 of 5

FEATURED COMPANIES

  • 3P Biopharmaceuticals
  • BioAgilytix
  • Cytovance Biologics
  • IDT Biologika
  • Nordic Nanovector
  • Sartorius Stedim Biotech
  • MORE

The “ADC Contract Manufacturing Market (3rd edition), 2018-2030” report offers a comprehensive study of the current scenario and future potential of the contract manufacturing market for ADCs. The study features an in-depth analysis, highlighting the capabilities of contract services providers engaged in this domain. In addition to other elements, the study includes:

  • An overview of the current status of the market with respect to the players involved in the manufacturing of ADCs. It features information on headquarters, size of the company, the types of services offered (antibody manufacturing / HPAPI or cytotoxic manufacturing / linker manufacturing / conjugation / fill-finish), location of manufacturing facilities, year of establishment of company / organization, scale of operations, and additional development services offered for ADCs (proof-of-concept studies / process development and scale-up / anaytical development).
  • Elaborate profiles of the contract service providers that are either one-stop-shops (offering services from antibody manufacturing to fill/ finish operations) or offer conjugation services at the commercial scale. Each profile provides a brief overview of the company, its financial information, details on ADC manufacturing capabilities, location of facilities, recent developments, and a comprehensive future outlook.
  • A comparative analysis of the key contract manufacturers based onvarious parameters, including company size, year of establishment, number of ADC manufacturing services offered, annual revenues, scale of operation, number of ADC development services offered and number of facilities for conjugation services.
  • An analysis of the recent investments (since 2012) made in this domain, the proceeds of which were intended to be used for the expansion or establishment of new facilities dedicated to offering ADC related services.
  • An analysis of the recent collaborations (since 2012) focused on manufacturing of ADCs on the basis of year in which the agreement was signed, type of agreement, key players and the geographical distribution of this activity.
  • An estimate of the overall ADC manufacturing / bioconjugation capacity (in grams / batch) of contract service providers based on information provided on their respective websites (wherever available) and additional data collated via secondary and primary research. The analysis highlights the distribution of global capacity by size of the company / organization (small-sized, mid-sized and large-sized) and geography (North America, Europe and Asia Pacific).
  • An overview of the ADCs that are already approved and those that are under development (clinical and preclinical), featuring information related to their current phase of development (wherever applicable), key target indications, developer company / organization, affiliated technology provider(s) and the type(s) of cytotoxin(s) and linker(s) used.
  • A review of the evolution of ADC conjugation technologies, highlighting the various types pf approaches that have been adopted in the past, and the different generations of linkers. It also highlights the competition between contemporary technology platforms.
  • A comprehensive geographical clinical trial analysis of completed, ongoing and planned studies of various ADCs (approved / under development). It provides details related to the different types of payloads and linkers investigated / being investigated across various geographies, based on the number of trials registered, current trial status, phase of development, number of patients enrolled and duration of the (recently initiated) trials (2015 onwards).
  • An informed estimate of the annual demand for ADC products (in grams), taking into account commercial, as well as clinical scale requirements, based on parameters such as target patient population, dosing frequency and dose strength of approved products and clinical stage candidates.
  • A discussion on affiliated trends, key drivers and challenges, under a SWOT framework, featuring a Harvey ball analysis, highlighting the relative impact of each SWOT parameter on the overall ADC contract manufacturing market.

One of the key objectives of this report was to evaluate the current opportunity and the future potential of the ADC contract manufacturing market over the coming decade. We have provided an informed estimate of the likely evolution of the market in the short to mid-term and long term, for the period 2018-2030. In addition, we have provided the likely distribution of the market based on scale of operation (commercial, phase III, phase II and phase I), component / process type (antibody manufacturing, HPAPI / cytotoxic production, conjugation / linker and fill / finish), target indications (solid tumors and hematological malignancies), type of payload used (auristatin, calicheamicin (ozogamicin), duocarmycin, DXd (exatecan derivative), maytansinoid, pyrrolobenzodiazepines (talirine, tesirine) and others), type of linker used (succinimidyl 4-(n-maleimidomethyl) cyclohexane-1-carboxylate, valine-citrulline, hydrazone, valine-alanine, n-succinimidyl-4-(2-pyridyldithio) butanoate and others) and geography (North America, Europe, Asia Pacific and rest of the world).

The research, analysis and insights presented in this report are backed by a deep understanding of key insights gathered from both secondary and primary research. Our opinions and insights presented in this study were influenced by discussions conducted with several key players in this domain. The report features detailed transcripts of interviews held with following stakeholders:

  • Aldo Braca (Chief Executive Officer, BSP Pharmaceuticals) and Giorgio Salciarini (Technical Business Development Manager, BSP Pharmaceuticals)
  • Anthony DeBoer (Director, Business Development, Synaffix)
  • Christian Bailly (Director of CDMO, Pierre Fabre)
  • Christian Rohlff (Chief Executive Officer & Founder, Oxford BioTherapeutics)
  • Jennifer L. Mitcham (Director,  Business Development, Catalent Pharma Solutions) and Stacy McDonald (Group Product Manager, Catalent Pharma Solutions)
  • John Burt (Chief Executive Officer, Abzena)
  • Laurent Ducry (Head of Bioconjugates Commercial Development, Lonza)
  • Mark Wright (Site Head, Piramal Healthcare)
  • Sasha Koniev (Chief Executive Officer & Co-Founder, Syndivia)
  • Anonymous (Director, Business Development, Leading CMO)
  • Anonymous (Chief Executive Officer, Leading CMO)

All actual figures have been sourced and analyzed from publicly available information forums and primary research discussions. Financial figures mentioned in this report are in USD, unless otherwise specified.

Example Highlights

  • The market landscape of ADC contract manufacturers is relatively niche with a limited number of companies presently offering contract services for manufacturing / conjugation of ADC products.  Of the total number of stakeholders, close to 15 players claim to be one-stop-shops, providing end-to-end services for all the steps of ADC manufacturing (antibody manufacturing to fill / finish). Examples of such players include  (in alphabetical order, no specific selection criteria) Abzena, Cambrex, Catalent Pharma Solutions, Goodwin Biotechnology and MabPlex.
  • Over 80% of ADC contract manufacturers are based in either North America or Europe with facilities dedicated to ADC manufacturing / conjugation located in one or multiple regions. Around 50% of the CMOs are large companies with more than 500 employees; examples of such players include (in alphabetical order, no specific selection criteria) Novasep, Pierre Fabre, and WuXi Biologics.
  • Contract manufacturers have made significant investments in expanding their respective capabilities and working capacities in order to address the growing demand for such services. Certain companies have also established new facilities dedicated to bioconjugation and / or manufacturing of highly potent / cytotoxic compounds. Over 60 of such developments were reported during the period 2012-H1 2018; of these, 65% of the instances were facility expansion project (focused on increasing facility area, and adding new manufacturing instruments and fill / finish lines).
  • Close to 80 ADCs are currently in the clinical stages of development. These candidates have been / are being evaluated in more than 400 clinical studies, with over 70,000 patients across the globe. A significant proportion of the current demand for ADC manufacturing (both in-house and outsourced) services is also driven by the four commercially available products. Our estimates  (based on parameters, such as target patient population and treatment regimen) suggest that the annual demand for ADCs (in grams) is likely to increase as more late-stage product candidates (phase II and above) receive regulatory approval over the coming decade. Currently, products being evaluated in clinical trials are estimated to contribute around 35% of the annual demand. Our projections indicate that, by 2030, commercialized products are likely to contribute to 90% of the demand for ADC manufacturing services.
  • With a limited number of players offering conjugation / ADC manufacturing services at the commercial scale, the combined global installed capacity available for manufacturing ADCs is estimated to be around 20-30 kgs. It is worth mentioning that a major share (over 90%) of the capacity is installed in facilities of mid-large CMOs, such as BSP Pharmaceuticals, Lonza, Merck / SAFC and Piramal Pharma Solutions. Around 55% of the global ADC manufacturing capacity is installed in facilities based in Europe. This is attributed to the large number of bioconjugation facilities that are presently situated in this region.
  • Driven by the rapidly evolving pipeline of ADC therapeutics and owing to the complex manufacturing requirements of such products, the trend of outsourcing is likely to persist  in the foreseen future. Overall, we expect the market to grow at an annualized rate of around 11.9% during the period 2018-2030. Contract manufacturing services for antibodies (for use in ADC production) (~40%) is currently responsible for generating the major share of revenues in this market, followed by conjugation and HPAPI manufacturing.
  • In terms of payload types, the demand for services related to manufacturing auristatin and maytansinoid based ADC therapeutics is high and estimated to contribute significantly (~75%) to the market’s revenues. However, the share of PBD based products is expected to grow at a relatively higher annualized rate of over 30% during the forecast period.
READ MORE
Note: Product cover images may vary from those shown
2 of 5

FEATURED COMPANIES

  • 3P Biopharmaceuticals
  • BioAgilytix
  • Cytovance Biologics
  • IDT Biologika
  • Nordic Nanovector
  • Sartorius Stedim Biotech
  • MORE

1. PREFACE
1.1. Scope of the Report
1.2. Research Methodology
1.3. Chapter Outlines

2. EXECUTIVE SUMMARY

3. INTRODUCTION
3.1. Chapter Overview
3.2. Essential Components of ADCs
3.2.1 Antibody
3.2.2. Cytotoxin
3.2.3. Linker
3.3. ADC Manufacturing
3.3.1. Key Steps
3.3.2. Technical Challenges
3.3.3. Growing Trend of Contract Manufacturing
3.4. Challenges Associated with Supply Chain and Method Transfer
3.4.1. Growing Demand for One Stop Shops and Integrated Service Providers
3.5. Selecting a CMO Partner

4. ADC CONTRACT MANUFACTURERS: CURRENT MARKET LANDSCAPE
4.1. Chapter Overview
4.2. ADC Contract Manufacturers: Overall Market Landscape
4.2.1. Distribution by Location of Headquarters
4.2.2. Distribution by Year of Establishment
4.2.3. Distribution by Company Size
4.2.4. Distribution by Service(s) Offered
4.2.5. Distribution by Location of Manufacturing Facility
4.2.6. Distribution by Scale of Operation
4.2.7. Distribution by Other ADC Services Offered
4.3. Antibody Manufacturing Service Providers
4.4. HPAPI / Cytotoxic Drug Manufacturing Service Providers

5. COMPANY PROFILES
5.1. Chapter Overview
5.2. Abzena
5.2.1. Company Overview and Financial Information
5.2.2. ADC Offerings
5.2.3. Manufacturing Facilities
5.2.4. Recent Developments
5.2.5. Future Outlook
5.3. Ajinomoto Althea
5.3.1. Company Overview and Financial Information
5.3.2. ADC Offerings
5.3.3. Manufacturing Facilities
5.3.4. Recent Developments
5.3.5. Future Outlook
5.4. BSP Pharmaceuticals
5.4.1. Company Overview and Financial Information
5.4.2. ADC Offerings
5.4.3. Manufacturing Facilities
5.4.4. Recent Developments
5.4.5. Future Outlook
5.5. CARBOGEN AMCIS
5.5.1. Company Overview and Financial Information
5.5.2. ADC Offerings
5.5.3. Manufacturing Facilities
5.5.4. Recent Developments
5.5.5. Future Outlook
5.6. Catalent Pharma Solutions
5.6.1. Company Overview and Financial Information
5.6.2. ADC Offerings
5.6.3. Manufacturing Facilities
5.6.4. Recent Developments
5.6.5. Future Outlook
5.7. Cerbios-Pharma
5.7.1. Company Overview and Financial Information
5.7.2. ADC Offerings
5.7.3. Manufacturing Facilities
5.7.4. Recent Developments
5.7.5. Future Outlook
5.8. Creative Biolabs
5.8.1. Company Overview and Financial Information
5.8.2. ADC Offerings
5.8.3. Manufacturing Facilities
5.8.4. Recent Developments
5.8.5. Future Outlook
5.9. Goodwin Biotechnology
5.9.1. Company Overview and Financial Information
5.9.2. ADC Offerings
5.9.3. Manufacturing Facilities
5.9.4. Recent Developments
5.9.5. Future Outlook
5.10. Levena Biopharma
5.10.1. Company Overview and Financial Information
5.10.2. ADC Offerings
5.10.3. Manufacturing Facilities
5.10.4. Recent Developments
5.10.5. Future Outlook
5.11. Lonza
5.11.1. Company Overview and Financial Information
5.11.2. ADC Offerings
5.11.3. Manufacturing Facilities
5.11.4. Recent Developments
5.11.5. Future Outlook
5.12. MabPlex
5.12.1. Company Overview and Financial Information
5.12.2. ADC Offerings
5.12.3. Manufacturing Facilities
5.12.4. Recent Developments
5.12.5. Future Outlook
5.13. Merck (SAFC)
5.13.1. Company Overview and Financial Information
5.13.2. ADC Offerings
5.13.3. Manufacturing Facilities
5.13.4. Recent Developments
5.13.5. Future Outlook
5.14. Novasep
5.14.1. Company Overview and Financial Information
5.14.2. ADC Offerings
5.14.3. Manufacturing Facilities
5.14.4. Recent Developments
5.14.5. Future Outlook
5.15. Pierre Fabre
5.15.1. Company Overview and Financial Information
5.15.2. ADC Offerings
5.15.3. Manufacturing Facilities
5.15.4. Recent Developments
5.15.5. Future Outlook
5.16. Piramal Pharma Solutions
5.16.1. Company Overview and Financial Information
5.16.2. ADC Offerings
5.16.3. Manufacturing Facilities
5.16.4. Recent Developments
5.16.5. Future Outlook
5.17. Syngene
5.17.1. Company Overview and Financial Information
5.17.2. ADC Offerings
5.17.3. Manufacturing Facilities
5.17.4. Recent Developments
5.17.5. Future Outlook
5.18. WuXi Biologics
5.18.1. Company Overview and Financial Information
5.18.2. ADC Offerings
5.18.3. Manufacturing Facilities
5.18.4. Recent Developments
5.18.5. Future Outlook

6. COMPANY COMPETITIVENESS ANALYSIS
6.1. Chapter Overview
6.2. Methodology
6.2.1. Assumptions and Parameters Evaluated
6.3. Affiliated Insights
6.3.1. Spider Web Competitive Analysis: Cambrex
6.3.2. Spider Web Competitive Analysis: Cerbios-Pharma
6.3.3. Spider Web Competitive Analysis: Merck (SAFC)
6.3.4. Spider Web Competitive Analysis: Novasep
6.3.5. Spider Web Competitive Analysis: Pierre Fabre
6.3.6. Spider Web Competitive Analysis: Piramal Pharma Solutions
6.3.7. Spider Web Competitive Analysis: WuXi Biologics

7. ADC CONTRACT MANUFACTURERS: FACILITY EXPANSIONS
7.1. Chapter Overview
7.2. ADC Contract Manufacturers: Recent Facility Expansions
7.2.1. Analysis by Year of Expansion
7.2.2. Analysis by Type of Expansion
7.2.3. Analysis by Type of Service Offered
7.2.4. Analysis by Type of Service and Year of Expansion
7.2.5. Analysis by Scale of Operation
7.2.6. Analysis by Location of Facility
7.2.7. Analysis by Scale of Operation and Location of Facility
7.2.8. Analysis by Key Players and Type of Expansion

8. ADC CONTRACT MANUFACTURERS: RECENT PARTNERSHIPS AND COLLABORATIONS
8.1. Chapter Overview
8.2. Partnership Models
8.3. ADC Contract Manufacturers: List of Partnerships and Collaborations
8.3.1. Analysis by Year of Partnership
8.3.2. Analysis by Type of Partnership
8.3.3. Key Players by Number of Partnerships
8.3.4. Regional Analysis
8.3.4.1. Most Active Players
8.3.4.2. Intercontinental and Intracontinental Agreements

9. ADC MANUFACTURING: CAPACITY ANALYSIS
9.1. Chapter Overview
9.2. Key Assumptions and Methodology
9.3. ADC Manufacturing: Overall Installed Global Capacity
9.3.1. Distribution by Size of Manufacturers
9.3.2. Distribution by Key Players
9.3.3. Distribution by Headquarters of Manufacturers
9.3.4. Distribution by Location of Manufacturing Facilities
9.3.4.1 By Country
9.3.4.2. By Continent

10. ADC THERAPEUTICS: MARKET OVERVIEW
10.1. Chapter Overview
10.2. ADC Therapeutics: Clinical Pipeline
10.2.1. Distribution by Phase of Development
10.2.2. Distribution by Indication
10.2.3. Distribution by Linker Type
10.2.4. Distribution by Payload Type
10.2.5. Distribution of Technology Providers by Number of Molecules
10.3. ADC Therapeutics: Preclinical / Discovery Pipeline
10.3.1. Distribution of Leading Players by Number of Molecules

11. ADC CONJUGATION TECHNOLOGY PLATFORMS
11.1. Chapter Overview
11.2. First Generation ADC Technologies
11.3. Second Generation ADC Technologies
11.3.1. Cysteine and Selenocysteine Engineering
11.3.2. Unnatural Amino Acid Engineering
11.3.3. Amino-Terminal Serine Engineering
11.4. Third Generation ADC Technologies
11.4.1. Enzyme-Assisted Ligation Approaches
11.4.2. Glycan Remodeling Approaches
11.4.3. Ligation at Fab Nucleotide-Binding Site
11.4.4. Cysteine Rebridging
11.4.5. Avoiding or Limiting Retro-Michael Drug Deconjugation
11.5. Evolutionary Analysis

12. GEOGRAPHICAL CLINICAL TRIALS ANALYSIS
12.1. Chapter Overview
12.2. Scope and Methodology
12.3. ADC Therapeutics: Overall Clinical Trial Analysis
12.3.1. Analysis by Trial Registration Year
12.3.2. Geographical Analysis by Number of Clinical Trials
12.3.3. Geographical Analysis by Enrolled Patient Population
12.4. ADC Therapeutics: Clinical Trial Analysis by Payload Type
12.4.1. Auristatin based Molecules
12.4.1.1. Geographical Analysis by Trial Phase and Recruitment Status
12.4.1.2. Geographical Analysis by Enrolled Patient Population
12.4.1.3. Analysis by Duration of Clinical Trials
12.4.2. Maytansinoid based Molecules
12.4.2.1. Geographical Analysis by Trial Phase and Recruitment Status
12.4.2.2. Geographical Analysis by Enrolled Patient Population
12.4.2.3. Analysis by Duration of Clinical Trials
12.4.3. Calicheamicin based Molecules
12.4.3.1. Geographical Analysis by Trial Phase and Recruitment Status
12.4.3.2. Geographical Analysis by Enrolled Patient Population
12.4.3.3. Analysis by Duration of Clinical Trials
12.4.4. PBDs (talirine, tesirine) based Molecules
12.4.4.1. Geographical Analysis by Trial Phase and Recruitment Status
12.4.4.2. Geographical Analysis by Enrolled Patient Population
12.4.4.3. Analysis by Duration of Clinical Trials
12.4.5. Duocarmycin based Molecules
12.4.5.1. Geographical Analysis by Trial Phase and Recruitment Status
12.4.5.2. Geographical Analysis by Enrolled Patient Population
12.4.5.3. Analysis by Duration of Clinical Trials
12.4.6. DXd (exatecan Derivative) based Molecules
12.4.6.1. Geographical Analysis by Trial Phase and Recruitment Status
12.4.6.2. Geographical Analysis by Enrolled Patient Population
12.4.6.3. Analysis by Duration of Clinical Trials
12.4.7. Molecules having Other Types of Payloads
12.4.7.1. Geographical Analysis by Trial Phase and Recruitment Status
12.4.7.2. Geographical Analysis by Enrolled Patient Population
12.4.7.3. Analysis by Duration of Clinical Trials
12.5. ADC Therapeutics: Clinical Trial Analysis by Linker Type
12.5.1. VC based Molecules
12.5.1.1. Geographical Analysis by Trial Phase and Recruitment Status
12.5.1.2. Geographical Analysis by Enrolled Patient Population
12.5.1.3. Analysis by Duration of Clinical Trials
12.5.2. Hydrazone Linker based Molecules
12.5.2.1. Geographical Analysis by Trial Phase and Recruitment Status
12.5.2.2. Geographical Analysis by Enrolled Patient Population
12.5.2.3. Analysis by Duration of Clinical Trials
12.5.3. SMCC based Molecules
12.5.3.1. Geographical Analysis by Trial Phase and Recruitment Status
12.5.3.2. Geographical Analysis by Enrolled Patient Population
12.5.3.3. Analysis by Duration of Clinical Trials
12.5.4. VA based Molecules
12.5.4.1. Geographical Analysis by Trial Phase and Recruitment Status
12.5.4.2. Geographical Analysis by Enrolled Patient Population
12.5.4.3. Analysis by Duration of Clinical Trials
12.5.5. SPDB based Molecules
12.5.5.1. Geographical Analysis by Trial Phase and Recruitment Status
12.5.5.2. Geographical Analysis by Enrolled Patient Population
12.5.5.3. Analysis by Duration of Clinical Trials
12.5.6. Molecules having Other Types of Linkers
12.5.6.1. Geographical Analysis by Trial Phase and Recruitment Status
12.5.6.2. Geographical Analysis by Enrolled Patient Population
12.5.6.3. Analysis by Duration of Clinical Trials

13. ADC THERAPEUTICS: DEMAND ANALYSIS
13.1. Chapter Overview
13.2. Key Assumptions and Methodology
13.3. ADC Therapeutics: Overall Annual Demand
13.3.1. ADC Therapeutics: Annual Commercial Demand
13.3.1.1. Distribution by Payload Type
13.3.1.2. Distribution by Linker Type
13.3.1.3. Distribution by Indication Type
13.3.2. ADC Therapeutics: Annual Clinical Demand
13.3.2.1. Distribution by Phase of Development
13.3.2.2. Distribution by Payload Type
13.3.2.3. Distribution by Linker Type
13.3.2.4. Distribution by Indication Type
13.3.2.5. Distribution by Region
13.3.3. ADC Therapeutics: Demand and Supply Analysis

14. MARKET SIZING AND OPPORTUNITY ANALYSIS
14.1. Chapter Overview
14.2. Forecast Methodology
14.3. Overall ADC Therapeutics Market, 2018-2030
14.4. Input Data and Key Assumptions
14.5. Overall ADC Contract Manufacturing Market, 2018-2030
14.5.1. ADC Contract Manufacturing Market, 2018-2030: Distribution by Component / Process Type
14.5.2. ADC Contract Manufacturing Market, 2018-2030: Distribution by Scale of Operation
14.6. ADC Contract Manufacturing Market for Commercial Products, 2018-2030
14.6.1. ADC Contract Manufacturing Market for Commercial Products, 2018-2030: Distribution by Components of ADC
14.6.2. ADC Contract Manufacturing Market for Commercial Products, 2018-2030: Distribution by Payload Type
14.6.3. ADC Contract Manufacturing Market for Commercial Products, 2018-2030: Distribution by Linker Type
14.6.4. ADC Contract Manufacturing Market for Commercial Products, 2018-2030: Distribution by Indication Type
14.6.5. ADC Contract Manufacturing Market for Commercial Products, 2018-2030: Distribution by Region
14.7. ADC Contract Manufacturing Market for Clinical Products, 2018-2030
14.7.1. ADC Contract Manufacturing Market for Clinical Products, 2018-2030: Distribution by Components of ADC
14.7.2. ADC Contract Manufacturing Market for Clinical Products, 2018-2030: Distribution by Payload Type
14.7.3. ADC Contract Manufacturing Market for Clinical Products, 2018-2030: Distribution by Linker Type
14.7.4. ADC Contract Manufacturing Market for Clinical Products, 2018-2030: Distribution by Indication Type
14.7.5. ADC Contract Manufacturing Market for Clinical Products, 2018-2030: Distribution by Region

15. SWOT ANALYSIS
15.1. Chapter Overview
15.1.1. Strengths
15.1.2. Weaknesses
15.1.3. Opportunities
15.1.4. Threats

16. CONCLUSION
16.1. Given the Growing Pipeline of ADC Therapeutics and Associated Manufacturing Challenges, Outsourcing is Considered to be a Viable Business Strategy in this Domain
16.2. Current Market Landscape is Relatively Niche with a Limited Number of Companies Offering End-To-End Services and a Few Players Providing Services at Commercial Scale
16.3. To Keep Pace with the Growing Demand for ADC Therapeutics, Many Contract Manufacturers Have Made Investments or Entered Into Strategic Alliances to Expand Existing Capabilities
16.4. Several Clinical Trials are being Conducted to Evaluate ADC Therapeutics Worldwide, the Majority of Such Studies being Centered in the US
16.5. Owing to the Presence of Several Small Companies and Start-Ups, the Trend of Outsourcing Such Operations is Likely to Flourish in the Coming Years
16.6. As More Late Stage Candidates Receive Approvals, the Annual Demand for ADC Therapeutics is Anticipated to Increase

17. INTERVIEW TRANSCRIPTS
17.1. Aldo Braca, Chief Executive Officer and Giorgio Salciarini, Technical Business Development Manager, BSP Pharmaceuticals
17.2. Anthony DeBoer (Director, Business Development, Synaffix)
17.3. Christian Bailly, Director of CDMO, Pierre Fabre
17.4. Christian Rohlff (Chief Executive Officer & Founder, Oxford BioTherapeutics)
17.5. Jennifer L. Mitcham, Director, Business Development and Stacy McDonald, Group Product Manager, Catalent Pharma Solutions
17.6. John Burt (Chief Executive Officer, Abzena)
17.7. Laurent Ducry, Head of Bioconjugates Commercial Development, Lonza
17.8. Mark Wright, Site Head, Piramal Healthcare
17.9. Sasha Koniev (Chief Executive Officer & Co-Founder, Syndivia)
17.10. Anonymous, Director, Business Development, Leading CMO
17.11. Anonymous, Chief Executive Officer, Leading CMO

18. APPENDIX 1: TABULATED DATA

19. APPENDIX 2: LIST OF COMPANIES AND ORGANIZATIONS

List of Figures
Figure 3.1 Components of an ADC
Figure 3.2 ADC Manufacturing Steps
Figure 4.1 ADC Contract Manufacturers: Distribution by Location of Headquarters
Figure 4.2 ADC Contract Manufacturers: Distribution by Year of Establishment
Figure 4.3 ADC Contract Manufacturers: Distribution by Company Size
Figure 4.4 ADC Contract Manufacturers: Distribution by Services Offered
Figure 4.5 ADC Contract Manufacturers: Distribution by Location of Headquarters and Services Offered
Figure 4.6 ADC Contract Manufacturers: Distribution by Location of Manufacturing Facilities
Figure 4.7 ADC Contract Manufacturers: Distribution by Scale of Operation
Figure 4.8 ADC Contract Manufacturers: Distribution based on Other Services Offered
Figure 6.1 Company Competitiveness Analysis: Assumptions and Key Parameters
Figure 6.2 Company Competitiveness Analysis: Dot-Plot Representation
Figure 6.3 Spider-Web Competitive Analysis: Cambrex
Figure 6.4 Spider-Web Competitive Analysis: Competitive Cerbios-Pharma
Figure 6.5 Spider-Web Competitive Analysis: Merck (SAFC)
Figure 6.6 Spider-Web Competitive Analysis: Novasep
Figure 6.7 Spider-Web Competitive Analysis: Pierre Fabre
Figure 6.8 Spider-Web Competitive Analysis: Piramal Pharma Solutions
Figure 6.9 Spider-Web Competitive Analysis: WuXi Biologics
Figure 7.1 ADC Contract Manufacturers: Facility Expansions, Distribution by Year, 2012-2018
Figure 7.2 ADC Contract Manufacturers: Distribution by Type of Recent Facility Expansion
Figure 7.3 ADC Contract Manufacturers: Facility Expansions, Distribution by Type of Service
Figure 7.4 ADC Contract Manufacturers: Facility Expansions, Distribution by Type of Service and Year of Expansion
Figure 7.5 ADC Contract Manufacturers: Facility Expansions, Distribution by Scale of Operation
Figure 7.6 ADC Contract Manufacturers: Facility Expansions, Distribution by Location of Facility
Figure 7.7 ADC Contract Manufacturers: Facility Expansions, Distribution by Scale of Operation and Location of Facility
Figure 7.8 ADC Contract Manufacturers: Facility Expansions, Distribution by Key Players and Type of Expansion
Figure 8.1 ADC Contract Manufacturing: Partnerships and Collaborations, Cumulative Trend by Year, 2012-2018
Figure 8.2 ADC Contract Manufacturing: Partnerships and Collaborations, Distribution by Type of Partnership
Figure 8.3 ADC Contract Manufacturing: Partnerships and Collaborations, Most Active Players
Figure 8.4 ADC Contract Manufacturing: Partnerships and Collaborations, Regional Distribution
Figure 8.5 ADC Contract Manufacturing: Partnerships and Collaborations, Intercontinental and Intracontinental Distribution
Figure 9.1 Overall ADC Installed Manufacturing Capacity: Distribution by Size of Manufacturers
Figure 9.2 Overall ADC Installed Manufacturing Capacity: Distribution by Key Players
Figure 9.3 Overall ADC Installed Manufacturing Capacity: Distribution by Headquarters of Manufacturers
Figure 9.4 Overall ADC Installed Manufacturing Capacity: Distribution by Location of Manufacturing Facilities (by Country)
Figure 9.5 Overall ADC Installed Manufacturing Capacity: Distribution by Location of Manufacturing Facilities (by Continent)
Figure 10.1 ADCs Clinical Pipeline: Distribution by Phase of Development
Figure 10.2 ADCs Clinical Pipeline: Distribution by Indication
Figure 10.3 ADCs Clinical Pipeline: Distribution by Type of Linker
Figure 10.4 ADCs Clinical Pipeline: Distribution by Type of Warhead
Figure 10.5 ADCs Clinical Pipeline: Distribution by Technology Providers
Figure 10.6 ADCs Preclinical / Discovery Pipeline: Relative Distribution of Key Technology Providers
Figure 11.1 ADC Conjugation Platforms: Technological Evolution
Figure 11.2 ADC Conjugation Platforms: Technology Landscape
Figure 12.1 ADC Therapeutics: Year-wise Trend of Clinical Trials
Figure 12.2 Geographical Clinical Trial Analysis: Distribution by Number of Trials
Figure 12.3 Geographical Clinical Trial Analysis: Distribution by Enrolled Patient Population
Figure 12.4 Geographical Clinical Trial Analysis: Distribution by Payload Type
Figure 12.5 Geographical Clinical Trial Analysis (Auristatin based Molecules): Distribution by Trial Phase and Recruitment Status
Figure 12.6 Geographical Clinical Trial Analysis (Auristatin based Molecules): Distribution by Enrolled Patient Population
Figure 12.7 Geographical Clinical Trial Analysis (Maytansinoid based Molecules): Distribution by Trial Phase and Recruitment Status
Figure 12.8 Geographical Clinical Trial Analysis (Maytansinoid based Molecules): Distribution by Enrolled Patient Population
Figure 12.9 Geographical Clinical Trial Analysis (Calicheamicin based Molecules): Distribution by Trial Phase and Recruitment Status
Figure 12.10 Geographical Clinical Trial Analysis (Calicheamicin based Molecules): Distribution by Enrolled Patient Population
Figure 12.11 Geographical Clinical Trial Analysis (PBDs based Molecules): Distribution by Trial Phase and Recruitment Status
Figure 12.12 Geographical Clinical Trial Analysis (PBDs based Molecules): Distribution by Enrolled Patient Population
Figure 12.13 Geographical Clinical Trial Analysis (Duocarmycin based Molecules): Distribution by Trial Phase and Recruitment Status
Figure 12.14 Geographical Clinical Trial Analysis (Duocarmycin based Molecules): Distribution by Enrolled Patient Population
Figure 12.15 Geographical Clinical Trial Analysis (DXd based Molecules): Distribution by Trial Phase and Recruitment Status
Figure 12.16 Geographical Clinical Trial Analysis (DXd based Molecules): Distribution by Enrolled Patient Population
Figure 12.17 Geographical Clinical Trial Analysis (Molecules having Other Types of Payloads): Distribution by Trial Phase and Recruitment Status
Figure 12.18 Geographical Clinical Trial Analysis (Molecules having Other Types of Payload): Distribution by Enrolled Patient Population
Figure 12.19 ADC Therapeutics: Geographical Clinical Trial Distribution by Linker Type
Figure 12.20 Geographical Clinical Trial Analysis (VC based Molecules): Distribution by Trial Phase and Recruitment Status
Figure 12.21 Geographical Clinical Trial Analysis (VC based Molecules): Distribution by Enrolled Patient Population
Figure 12.22 Geographical Clinical Trial Analysis (Hydrazone Linker based Molecules): Distribution by Trial Phase and Recruitment Status
Figure 12.23 Geographical Clinical Trial Analysis (Hydrazone Linker based Molecules): Distribution by Enrolled Patient Population
Figure 12.24 Geographical Clinical Trial Analysis (SMCC based Molecules): Distribution by Trial Phase and Recruitment Status
Figure 12.25 Geographical Clinical Trial Analysis (SMCC based Molecules): Distribution by Enrolled Patient Population
Figure 12.26 Geographical Clinical Trial Analysis (VA based Molecules): Distribution by Trial Phase and Recruitment Status
Figure 12.27 Geographical Clinical Trial Analysis (VA based Molecules): Distribution by Trial Phase and Recruitment Status
Figure 12.28 Geographical Clinical Trial Analysis (SPDB based Molecules): Distribution by Trial Phase and Recruitment Status
Figure 12.29 Geographical Clinical Trial Analysis (SPDB based Molecules): Distribution by Enrolled Patient Population
Figure 12.30 Geographical Clinical Trial Analysis (Molecules having Other Types of Linkers): Distribution by Trial Phase and Recruitment Status
Figure 12.31 Geographical Clinical Trial Analysis (Molecules having Other Types of Linkers): Distribution by Enrolled Patient Population
Figure 13.1 ADC Therapeutics: Overall Annual Demand
Figure 13.2 ADC Therapeutics: Overall Annual Demand, Distribution by Scale of Operation
Figure 13.3 ADC Therapeutics: Overall Annual Commercial Demand
Figure 13.4 Annual Commercial Demand: Distribution by Payload Type
Figure 13.5 Annual Commercial Demand: Distribution by Linker Type
Figure 13.6 Annual Commercial Demand: Distribution by Indication Type
Figure 13.7 ADC Therapeutics: Overall Annual Clinical Demand
Figure 13.8 Annual Clinical Demand: Distribution by Phase of Development
Figure 13.9 Annual Clinical Demand: Distribution by Payload Type
Figure 13.10 Annual Clinical Demand: Distribution by Linker Type
Figure 13.11 Annual Clinical Demand: Distribution by Indication
Figure 13.12 Annual Clinical Demand: Distribution by Region
Figure 13.13 ADC Therapeutics: Demand and Supply Analysis, 2018 - 2030
Figure 14.1 Overall ADC Therapeutics Market, 2018-2030 (USD Billion)
Figure 14.2 ADC Therapeutics: Relative Cost of Manufacturing by Component / Process Type
Figure 14.3 ADC Contract Manufacturing Market, 2018-2030: Distribution by Component / Process Type
Figure 14.4 ADC Contract Manufacturing Market, 2018-2030: Distribution by Scale of Operation
Figure 14.5 ADC Contract Manufacturing Market for Commercial Products, 2018-2030: Distribution by Components of ADC
Figure 14.6 ADC Contract Manufacturing Market for Commercial Products, 2018-2030: Distribution by Payload Type
Figure 14.7 ADC Contract Manufacturing Market for Commercial Products, 2018-2030: Distribution by Linker Type
Figure 14.8 ADC Contract Manufacturing Market for Commercial Products, 2018-2030: Distribution by Indication Type
Figure 14.9 ADC Contract Manufacturing Market for Commercial Products, 2018-2030: Distribution by Region
Figure 14.10 ADC Contract Manufacturing Market for Clinical Products, 2018-2030: Distribution by Components of ADC
Figure 14.11 ADC Contract Manufacturing Market for Clinical Products, 2018-2030: Distribution by Payload Type
Figure 14.12 ADC Contract Manufacturing Market for Clinical Products, 2018-2030: Distribution by Linker Type
Figure 14.13 ADC Contract Manufacturing Market for Clinical Products, 2018-2030: Distribution by Indication Type
Figure 14.14 ADC Contract Manufacturing Market for Clinical Products, 2018-2030: Distribution by Region
Figure 15.1 SWOT Analysis: Harvey Ball Analysis
Figure 16.1 ADC Contract Manufacturing Market: Conservative, Base and Optimistic Scenario, 2018, 2025 and 2030 (USD Billion)

List of Tables
Table 3.1 Commonly used Cytotoxins for ADC Therapeutics
Table 3.2 OEL Bands, Safebridge Consultants
Table 4.1 ADC Contract Manufacturers: List of Service Providers
Table 4.2 ADC Contract Manufacturers: Services Offered
Table 4.3 ADC Contract Manufacturers: Details on Manufacturing Facilities
Table 4.4 ADC Contract Manufacturers: Details on Scale of Production and Capacity
Table 4.5 ADC Contract Manufacturers: Details on Other Services Offered
Table 4.6 ADC Contract Manufacturers: List of Antibody Manufacturing Service Providers
Table 4.7 ADC Contract Manufacturers: List of HPAPI and Cytotoxic Drug Manufacturing Service Providers
Table 5.1 Abzena: Company Overview and Financial Information
Table 5.2 Abzena: ADC Related Offerings
Table 5.3 Abzena: Manufacturing Facilities Information
Table 5.4 Abzena: Recent Developments
Table 5.5 Abzena: Future Outlook
Table 5.6 Ajinomoto Althea: Company Overview and Financial Information
Table 5.7 Ajinomoto Althea: ADC Related Offerings
Table 5.8 Ajinomoto Althea: Manufacturing Facilities Information
Table 5.9 Ajinomoto Althea: Recent Developments
Table 5.10 Ajinomoto Althea: Future Outlook
Table 5.11 BSP Pharmaceuticals: Company Overview
Table 5.12 BSP Pharmaceuticals: ADC Related Offerings
Table 5.13 BSP Pharmaceuticals: Manufacturing Facilities Information
Table 5.14 BSP Pharmaceuticals: Recent Developments
Table 5.15 BSP Pharmaceuticals: Future Outlook
Table 5.16 CARBOGEN AMCIS: Company Overview and Financial Information
Table 5.17 CARBOGEN AMCIS: ADC Related Offerings
Table 5.18 CARBOGEN AMCIS: Manufacturing Facilities Information
Table 5.19 CARBOGEN AMCIS: Recent Developments
Table 5.20 Catalent Pharma Solutions: Company Overview and Financial Information
Table 5.21 Catalent Pharma Solutions: ADC Related Offerings
Table 5.22 Catalent Pharma Solutions: Manufacturing Facilities Information
Table 5.23 Catalent Pharma Solutions: Recent Developments
Table 5.24 Catalent Pharma Solutions: Future Outlook
Table 5.25 Cerbios-Pharma: Company Overview and Financial Information
Table 5.26 Cerbios-Pharma: ADC Related Offerings
Table 5.27 Cerbios-Pharma: Manufacturing Facilities Information
Table 5.28 Cerbios-Pharma: Recent Developments
Table 5.29 Cerbios-Pharma: Future Outlook
Table 5.30 Creative Biolabs: Company Overview
Table 5.31 Creative Biolabs: ADC Related Offerings
Table 5.32 Creative Biolabs: Manufacturing Facilities Information
Table 5.33 Creative Biolabs: Recent Developments
Table 5.34 Creative Biolabs: Future Outlook
Table 5.35 Goodwin Biotechnology: Company Overview and Financial Information
Table 5.36 Goodwin Biotechnology: ADC Related Offerings
Table 5.37 Goodwin Biotechnology: Manufacturing Facilities Information
Table 5.38 Goodwin Biotechnology: Recent Developments
Table 5.39 Goodwin Biotechnology: Future Outlook
Table 5.40 Levena Biopharma: Company Overview and Financial Information
Table 5.41 Levena Biopharma: ADC Related Offerings
Table 5.42 Levena Biopharma: Manufacturing Facilities Information
Table 5.43 Levena Biopharma: Recent Developments
Table 5.44 Levena Biopharma: Future Outlook
Table 5.45 Lonza: Company Overview and Financial Information
Table 5.46 Lonza: ADC Related Offerings
Table 5.47 Lonza: Manufacturing Facilities Information
Table 5.48 Lonza: Recent Developments
Table 5.49 Lonza: Future Outlook
Table 5.50 MabPlex: Company Overview and Financial Information
Table 5.51 MabPlex: ADC Related Offerings
Table 5.52 MabPlex: Manufacturing Facilities Information
Table 5.53 MabPlex: Recent Developments
Table 5.54 MabPlex: Future Outlook
Table 5.55 Merck (SAFC): Company Overview and Financial Information
Table 5.56 Merck (SAFC): ADC Related Offerings
Table 5.57 Merck (SAFC): Information on Manufacturing Facilities
Table 5.58 Merck (SAFC): Recent Developments
Table 5.59 Merck (SAFC): Future Outlook
Table 5.60 Novasep: Company Overview and Financial Information
Table 5.61 Novasep: ADC Related Offerings
Table 5.62 Novasep: Manufacturing Facilities Information
Table 5.63 Novasep: Recent Developments
Table 5.64 Novasep: Future Outlook
Table 5.65 Pierre Fabre: Company Overview and Financial Information
Table 5.66 Pierre Fabre: ADC Related Offerings
Table 5.67 Pierre Fabre: Manufacturing Facilities Information
Table 5.68 Pierre Fabre: Recent Developments
Table 5.69 Pierre Fabre: Future Outlook
Table 5.70 Piramal Pharma Solutions: Company Overview and Financial Information
Table 5.71 Piramal Pharma Solutions: ADC Related Offerings
Table 5.72 Piramal Pharma Solutions: Manufacturing Facilities Information
Table 5.73 Piramal Pharma Solutions: Recent Developments
Table 5.74 Piramal Pharma Solutions: Future Outlook
Table 5.75 Syngene: Company Overview and Financial Information
Table 5.76 Syngene: ADC Related Offerings
Table 5.77 Syngene: Information on Manufacturing Facilities
Table 5.78 Syngene: Recent Developments
Table 5.79 Syngene: Future Outlook
Table 5.80 WuXi Biologics: Company Overview and Financial Information
Table 5.81 WuXi Biologics: ADC Related Offerings
Table 5.82 WuXi Biologics: Manufacturing Facilities Information
Table 5.83 WuXi Biologics: Recent Developments
Table 5.84 WuXi Biologics: Future Outlook
Table 6.1 Company Competitiveness Analysis: Shortlisted Players
Table 6.2 Company Competitiveness Analysis: Spiderweb Parameters for Shortlisted Players
Table 7.1 ADC Contract Manufacturing: Recent Developments
Table 8.1 ADC Contract Manufacturing: Partnerships and Collaborations, 2012-2018
Table 8.2 ADC Contract Manufacturing Partnerships: Most Active Players
Table 9.1 ADC Manufacturing Installed Global Capacity: Average Capacity in Grams (Sample Data Set)
Table 9.2 ADC Manufacturing Installed Global Capacity in Grams: Total Capacity by Size of Manufacturers
Table 10.1 ADC Therapeutics: Clinical Pipeline
Table 10.2 ADC Therapeutics: Clinical Pipeline (Information on Linkers and Payloads)
Table 10.3 ADC Therapeutics: Preclinical / Discovery Pipeline
Table 11.1 Second Generation ADC Technologies: Cysteine and Selenocysteine Engineering
Table 11.2 Second Generation ADC Technologies: Unnatural Amino Acid Engineering
Table 11.3 Second Generation ADC Technologies: Amino-terminal Engineered Serine
Table 11.4 Third Generation ADC Technologies: Enzyme-Assisted Ligation Approaches
Table 11.5 Third Generation ADC Technologies: Glycan Remodeling Approaches
Table 11.6 Third Generation ADC Technologies: Enzyme-Assisted Ligation Approaches
Table 11.7 Third Generation ADC Technologies: Cysteine Rebridging
Table 11.8 Third Generation ADC Technologies: Avoiding or Limiting Retro-Michael Drug Deconjugation
Table 12.1 Geographical Clinical Trial Analysis (Auristatin Based Molecules): Duration of Trials
Table 12.2 Geographical Clinical Trial Analysis (Maytansinoid Based Molecules): Duration of Trials
Table 12.3 Geographical Clinical Trial Analysis (Calicheamicin Based Molecules): Duration of Trials
Table 12.4 Geographical Clinical Trial Analysis (PBDs Based Molecules): Duration of Trials
Table 12.5 Geographical Clinical Trial Analysis (Duocarmycin Based Molecules): Duration of Trials
Table 12.6 Geographical Clinical Trial Analysis (DXd Based Molecules): Duration of Trials
Table 12.7 Geographical Clinical Trial Analysis (Other Types of Payload based Molecules): Duration of the Trials
Table 12.8 Geographical Clinical Trial Analysis (VC based Molecules): Duration of the Trials
Table 12.9 Geographical Clinical Trial Analysis (Hydrazone Linker Based Molecules): Duration of Trials
Table 12.10 Geographical Clinical Trial Analysis (SMCC Based Molecules): Duration of Trials
Table 12.11 Geographical Clinical Trial Analysis (Auristatin Based Molecules): Duration of Trials
Table 12.12 Geographical Clinical Trial Analysis (Auristatin Based Molecules): Duration of Trials
Table 12.13 Other Types of Linkers based ADC Therapeutics: Duration of the Trials
Table 14.1 Late Stage ADCs: Development Status
Table 14.2 ADC Therapeutics: Outsourcing Activity for Late Stage Molecules
Table 18.1 ADC Contract Manufacturers: Distribution by Location of Headquarters
Table 18.2 ADC Contract Manufacturers: Distribution by Year of Establishment
Table 18.3 ADC Contract Manufacturers: Distribution by Company Size
Table 18.4 ADC Contract Manufacturers: Distribution by Services Offered
Table 18.5 ADC Contract Manufacturers: Distribution by Location of Headquarters and Services Offered
Table 18.6 ADC Contract Manufacturers: Distribution by Location of Manufacturing Facilities
Table 18.7 ADC Contract Manufacturers: Distribution by Scale of Operation
Table 18.8 ADC Contract Manufacturers: Distribution based on Other Services Offered
Table 18.9 ADC Contract Manufacturers: Facility Expansions, Distribution by Year, 2012-2018
Table 18.10 ADC Contract Manufacturers: Distribution by Type of Recent Facility Expansion
Table 18.11 ADC Contract Manufacturers: Facility Expansions, Distribution by Type of Service
Table 18.12 ADC Contract Manufacturers: Facility Expansions, Distribution by Type of Service and Year of Expansion
Table 18.13 ADC Contract Manufacturers: Facility Expansions, Distribution by Scale of Operation
Table 18.14 ADC Contract Manufacturers: Facility Expansions, Distribution by Location of Facility
Table 18.15 ADC Contract Manufacturers: Facility Expansions, Distribution by Scale of Operation and Location of Facility
Table 18.16 ADC Contract Manufacturers: Facility Expansions, Distribution by Key Players and Type of Expansion
Table 18.17 ADC Contract Manufacturing: Partnerships and Collaborations, Cumulative Trend by Year, 2012-2018
Table 18.18 ADC Contract Manufacturing: Partnerships and Collaborations, Distribution by Type of Partnership
Table 18.19 ADC Contract Manufacturing: Partnerships and Collaborations, Most Active Players
Table 18.20 ADC Contract Manufacturing: Partnerships and Collaborations, Regional Distribution
Table 18.21 ADC Contract Manufacturing: Partnerships and Collaborations, Intercontinental and Intracontinental Distribution
Table 18.22 Overall ADC Installed Manufacturing Capacity: Distribution by Size of Manufacturers
Table 18.23 Overall ADC Installed Manufacturing Capacity: Distribution by Key Players
Table 18.24 Overall ADC Installed Manufacturing Capacity: Distribution by Headquarters of Manufacturers
Table 18.25 Overall ADC Installed Manufacturing Capacity: Distribution by Location of Manufacturing Facilities (by Country)
Table 18.26 Overall ADC Installed Manufacturing Capacity: Distribution by Location of Manufacturing Facilities (by Continent)
Table 18.27 ADCs Clinical Pipeline: Distribution by Phase of Development
Table 18.28 ADCs Clinical Pipeline: Distribution by Indication
Table 18.29 ADCs Clinical Pipeline: Distribution by Type of Linker
Table 18.30 ADCs Clinical Pipeline: Distribution by Type of Warhead
Table 18.31 ADCs Clinical Pipeline: Distribution by Technology Providers
Table 18.32 ADCs Preclinical / Discovery Pipeline: Relative Distribution of Key Technology Providers
Table 18.33 ADC Therapeutics: Year-wise Trend of Clinical Trials
Table 18.34 Geographical Clinical Trial Analysis: Distribution by Number of Trials
Table 18.35 Geographical Clinical Trial Analysis: Distribution by Enrolled Patient Population
Table 18.36 Geographical Clinical Trial Analysis: Distribution by Payload Type
Table 18.37 Geographical Clinical Trial Analysis (Auristatin based Molecules): Distribution by Trial Phase and Recruitment Status
Table 18.38 Geographical Clinical Trial Analysis (Auristatin based Molecules): Distribution by Enrolled Patient Population
Table 18.39 Geographical Clinical Trial Analysis (Maytansinoid based Molecules): Distribution by Trial Phase and Recruitment Status
Table 18.40 Geographical Clinical Trial Analysis (Maytansinoid based Molecules): Distribution by Enrolled Patient Population
Table 18.41 Geographical Clinical Trial Analysis (Calicheamicin based Molecules): Distribution by Trial Phase and Recruitment Status
Table 18.42 Geographical Clinical Trial Analysis (Calicheamicin based Molecules): Distribution by Enrolled Patient Population
Table 18.43 Geographical Clinical Trial Analysis (PBDs based Molecules): Distribution by Trial Phase and Recruitment Status
Table 18.44 Geographical Clinical Trial Analysis (PBDs based Molecules): Distribution by Enrolled Patient Population
Table 18.45 Geographical Clinical Trial Analysis (Duocarmycin based Molecules): Distribution by Trial Phase and Recruitment Status
Table 18.46 Geographical Clinical Trial Analysis (Duocarmycin based Molecules): Distribution by Enrolled Patient Population
Table 18.47 Geographical Clinical Trial Analysis (DXd based Molecules): Distribution by Trial Phase and Recruitment Status
Table 18.48 Geographical Clinical Trial Analysis (DXd based Molecules): Distribution by Enrolled Patient Population
Table 18.49 Geographical Clinical Trial Analysis (Molecules having Other Types of Payloads): Distribution by Trial Phase and Recruitment Status
Table 18.50 Geographical Clinical Trial Analysis (Molecules having Other Types of Payload): Distribution by Enrolled Patient Population
Table 18.51 ADC Therapeutics: Geographical Clinical Trial Distribution by Linker Type
Table 18.52 Geographical Clinical Trial Analysis (VC based Molecules): Distribution by Trial Phase and Recruitment Status
Table 18.53 Geographical Clinical Trial Analysis (VC based Molecules): Distribution by Enrolled Patient Population
Table 18.54 Geographical Clinical Trial Analysis (Hydrazone Linker based Molecules): Distribution by Trial Phase and Recruitment Status
Table 18.55 Geographical Clinical Trial Analysis (Hydrazone Linker based Molecules): Distribution by Enrolled Patient Population
Table 18.56 Geographical Clinical Trial Analysis (SMCC based Molecules): Distribution by Trial Phase and Recruitment Status
Table 18.57 Geographical Clinical Trial Analysis (SMCC based Molecules): Distribution by Enrolled Patient Population
Table 18.58 Geographical Clinical Trial Analysis (VA based Molecules): Distribution by Trial Phase and Recruitment Status
Table 18.59 Geographical Clinical Trial Analysis (VA based Molecules): Distribution by Trial Phase and Recruitment Status
Table 18.60 Geographical Clinical Trial Analysis (SPDB based Molecules): Distribution by Trial Phase and Recruitment Status
Table 18.61 Geographical Clinical Trial Analysis (SPDB based Molecules): Distribution by Enrolled Patient Population
Table 18.62 Geographical Clinical Trial Analysis (Molecules having Other Types of Linkers): Distribution by Trial Phase and Recruitment Status
Table 18.63 Geographical Clinical Trial Analysis (Molecules having Other Types of Linkers): Distribution by Enrolled Patient Population
Table 18.64 ADC Therapeutics: Overall Annual Demand
Table 18.65 ADC Therapeutics: Overall Annual Demand, Distribution by Scale of Operation
Table 18.66 ADC Therapeutics: Overall Annual Commercial Demand
Table 18.67 Annual Commercial Demand: Distribution by Payload Type
Table 18.68 Annual Commercial Demand: Distribution by Linker Type
Table 18.69 Annual Commercial Demand: Distribution by Indication Type
Table 18.70 ADC Therapeutics: Overall Annual Clinical Demand
Table 18.71 Annual Clinical Demand: Distribution by Phase of Development
Table 18.72 Annual Clinical Demand: Distribution by Payload Type
Table 18.73 Annual Clinical Demand: Distribution by Linker Type
Table 18.74 Annual Clinical Demand: Distribution by Indication
Table 18.75 Annual Clinical Demand: Distribution by Region
Table 18.76 Overall ADC Therapeutics Market: Conservative, Base and Optimistic Scenarios, 2018-2030 (USD Billion)
Table 18.77 ADC Therapeutics: Relative Cost of Manufacturing by Component / Process Type
Table 18.78 ADC Contract Manufacturing Market, 2018-2030: Distribution by Component / Process Type, Conservative, Base and Optimistic Scenarios
Table 18.79 ADC Contract Manufacturing Market, 2018-2030: Distribution by Scale of Operation, Conservative, Base and Optimistic Scenarios
Table 18.80 ADC Contract Manufacturing Market for Commercial Products, 2018-2030: Distribution by Component / Process Type, Conservative, Base and Optimistic Scenarios
Table 18.81 ADC Contract Manufacturing Market for Commercial Products, 2018-2030: Distribution by Payload Type, Conservative, Base and Optimistic Scenarios
Table 18.82 ADC Contract Manufacturing Market for Commercial Products, 2018-2030: Distribution by Linker Type, Conservative, Base and Optimistic Scenarios
Table 18.83 ADC Contract Manufacturing Market for Commercial Products, 2018-2030: Distribution by Indication Type, Conservative, Base and Optimistic Scenarios
Table 18.84 ADC Contract Manufacturing Market for Commercial Products, 2018-2030: Distribution by Region, Conservative, Base and Optimistic Scenarios
Table 18.85 ADC Contract Manufacturing Market for Clinical Products, 2018-2030: Distribution by Components of ADC, Conservative, Base and Optimistic Scenarios
Table 18.86 ADC Contract Manufacturing Market for Clinical Products, 2018-2030: Distribution by Payload Type, Conservative, Base and Optimistic Scenarios
Table 18.87 ADC Contract Manufacturing Market for Clinical Products, 2018-2030: Distribution by Linker Type, Conservative, Base and Optimistic Scenarios
Table 18.88 ADC Contract Manufacturing Market for Clinical Products, 2018-2030: Distribution by Indication Type, Conservative, Base and Optimistic Scenarios
Table 18.89 ADC Contract Manufacturing Market for Clinical Products, 2018-2030: Distribution by Region, Conservative, Base and Optimistic Scenarios
Table 18.90 SWOT Analysis: Harvey Ball Analysis
Table 18.91 ADC Contract Manufacturing Market: Conservative, Base and Optimistic Scenario, 2018, 2025 and 2030 (USD Billion)

Note: Product cover images may vary from those shown
3 of 5

Loading
LOADING...

4 of 5

FEATURED COMPANIES

  • 3P Biopharmaceuticals
  • BioAgilytix
  • Cytovance Biologics
  • IDT Biologika
  • Nordic Nanovector
  • Sartorius Stedim Biotech
  • MORE

Research Methodology
The data presented in this report has been gathered via secondary and primary research. For all our projects, we conduct interviews with experts in the area (academia, industry, medical practice and other associations) to solicit their opinions on emerging trends in the market. This is primarily useful for us to draw out our own opinion on how the market may evolve across different regions and technology segments. Wherever possible, the available data has been checked for accuracy from multiple sources of information.
The secondary sources of information include:

  • Annual reports
  • Investor presentations
  • SEC filings
  • Industry databases
  • News releases from company websites
  • Government policy documents
  • Industry analysts’ views

While the focus has been on forecasting the market over the period 2018-2030, the report also provides our independent view on various technological and non-commercial trends emerging in the industry. This opinion is solely based on our knowledge, research and understanding of the relevant market gathered from various secondary and primary sources of information.

Chapter Outlines
Chapter 2 provides an executive summary of the insights captured during our research. It offers a high-level view on the likely evolution of the ADC contract manufacturing market in the mid to long term.

Chapter 3 is a general introduction to ADCs and the manufacturing requirements of such therapeutic products. It includes a detailed discussion on the structure of an ADC and its various components, manufacturing steps and associated challenges. The chapter also provides an overview of the growing trend of contract manufacturing, along with the challenges associated with the supply chain and the growing demand for one-stop-shops. Further, it features a discussion on the various parameters that a sponsor company needs to consider while selecting a contract manufacturing partner.

Chapter 4 provides a comprehensive overview of contract manufacturers that are actively involved in the production or conjugation of ADCs. The chapter features information on headquarters, size of the company, types of services offered (antibody manufacturing / HPAPI or cytotoxic manufacturing / linker manufacturing / conjugation / fill-finish), location of manufacturing facilities, year of establishment of company / organization, scale of operation, and additional development services offered for ADCs (proof-of-concept studies / process development and scale-up / analytical development). The chapter also includes a list of various contract manufacturers offering antibody production services along with the information on the location of their headquarters. Further, it provides a list of HPAPI / cytotoxic drug manufacturers along with the information on the location of facilities dedicated to the manufacturing of such components.

Chapter 5 features profiles of contract service providers that are either one-stop-shops (offering services from antibody manufacturing to fill/ finish operations) or offer conjugation services at the commercial scale. Each profile provides a brief overview of the company, its financial information, details on ADC manufacturing capabilities, the location of facilities, recent developments, and a comprehensive future outlook.

Chapter 6 features a detailed comparative analysis of the ADC contract manufacturers. The companies were compared on the basis of various parameters including company size, year of establishment, number of ADC manufacturing services offered, annual revenues, the scale of operation, number of ADC development services offered and number of facilities for conjugation services. The results of this analysis were used to highlight the features of the most competent companies working in this domain.

Chapter 7 highlights the investments made by CMOs to expand or set up new facilities in order to support their ongoing operations. For each such instance, we have provided information on month/year of the development, type of development, amount invested (if available), focus area (manufacturing, analytical / development and fill / finish), scale of operation (preclinical, clinical and commercial) and location of the facility in which the investment was made.

Chapter 8 features an elaborate discussion and analysis of the various collaborations and partnerships that have been inked between different players in this market. We have also discussed the different partnership models (including research agreements, manufacturing agreements, technology licensing agreements, product development agreements and acquisitions/mergers) and the most common forms of deals/agreements that have been established between 2012-H1 2018. It consists of a schematic representation showcasing the players that have established the maximum number of alliances related to the manufacturing of ADCs. Furthermore, we have provided a world map representation of the deals inked in this field, highlighting those that have been established within and across different continents.

Chapter 9 features a comprehensive analysis of the overall installed manufacturing/bioconjugation capacity of contract service providers and an estimate of the quantity of ADCs that can be produced per batch. The analysis highlights the distribution of global capacity by the size of the company/organization (small-sized, mid-sized and large-sized) and geography (North America, Europe and Asia Pacific).

Chapter 10 provides a comprehensive overview of the market landscape of ADCs that are already approved and those that are under development (clinical and preclinical). This chapter includes information related to their current phase of development (wherever applicable), key target indications, developer company/organization, affiliated technology provider(s) and the type(s) of cytotoxin(s) and linker(s) used.

Chapter 11 features an elaborate discussion and competitive analysis of the various ADC conjugation approaches. This chapter also features an overview of the evolution of these technologies, highlighting the competition between contemporary technology platforms.

Chapter 12 features a comprehensive geographical clinical trial analysis of completed, ongoing and planned studies of various ADCs (approved / under development). The analysis provides details related to the different types of payloads and linkers investigated/being investigated across various geographies, based on the number of trials registered, current trial status, the phase of development, number of patients enrolled and duration of the (recently initiated) trials (2015 onwards).

Chapter 13 features a comprehensive analysis of the annual demand of ADCs (in grams) taking into account commercial, as well as clinical scale requirements. This was based on the parameters such as target patient population, dosing frequency and dose strength of approved products and clinical stage candidates.

Chapter 14 presents a comprehensive market forecast analysis, highlighting the likely growth of the contract manufacturing market of ADCs, till 2030. The chapter provides likely distribution of the projected future opportunity based on scale of operation (commercial, phase III, phase II and phase I), component / process type (antibody, cytotoxic / linker, conjugation, fill/finish and others), target indications (solid tumors and hematological malignancies), type of payload used (auristatin, calicheamicin (ozogamicin), duocarmycin, DXd (exatecan derivative), maytansinoid, pyrrolobenzodiazepines (talirine, tesirine) and others), type of linker used (succinimidyl 4-(n-maleimidomethyl) cyclohexane-1-carboxylate, valine-citrulline, hydrazone, valine-alanine, n-succinimidyl-4-(2-pyridyldithio) butanoate and others) and geography (North America, Europe, Asia Pacific and rest of the world).

Chapter 15 provides a detailed analysis capturing the key parameters and trends that are likely to influence the future of ADC contract manufacturing market, under a comprehensive SWOT framework.

Chapter 16 is a summary of the overall report. In this chapter, we have provided a list of key takeaways from the report, and expressed our independent opinion related to the research and analysis described in the previous chapters.

Chapter 17 is a collection of interview transcripts of the discussions that were held with key stakeholders in this market. The chapter provides details of interviews held with  Aldo Braca (Chief Executive Officer, BSP Pharmaceuticals) and Giorgio Salciarini (Technical Business Development Manager, BSP Pharmaceuticals), Anthony DeBoer (Director, Business Development, Synaffix), Christian Bailly (Director of CDMO, Pierre Fabre), Christian Rohlff (Chief Executive Officer & Founder, Oxford BioTherapeutics), Jennifer L. Mitcham (Director,  Business Development, Catalent Pharma Solutions) and Stacy McDonald (Group Product Manager, Catalent Pharma Solutions), John Burt (Chief Executive Officer, Abzena), Laurent Ducry (Head of Bioconjugates Commercial Development, Lonza), Mark Wright (Site Head, Piramal Healthcare), Sasha Koniev (Chief Executive Officer & Co-Founder, Syndivia), Anonymous (Director, Business Development, Leading CMO) and Anonymous (Chief Executive Officer, Leading CMO)

Chapter 18 is an appendix, which provides tabulated data and numbers for all the figures included in the report.

Chapter 19 is an appendix, which provides the list of companies and organizations mentioned in the report.

Note: Product cover images may vary from those shown
5 of 5
  • 3P Biopharmaceuticals
  • AB Sciex
  • AbbVie
  • AbGenomics
  • ABL Bio
  • Abzena
  • ACES Pharma
  • Adar Biotech
  • ADC Biotechnology
  • ADC Therapeutics
  • Advanced BioScience Laboratories
  • Aesica Pharmaceuticals
  • Affinity Life Sciences
  • Agensys
  • Agno Pharma
  • Ajinomoto Althea
  • Alcami
  • Aldevron
  • Alkermes
  • Allozyne
  • Almac
  • Alpha Cancer Technologies
  • Alphora Research
  • Alteogen
  • Amatsigroup
  • Ambrx
  • Amgen
  • AMPAC Fine Chemicals
  • AMRI
  • Angiex
  • Anogen
  • APO-T
  • Aptuit
  • AqueaTether Therapeutics
  • Arabio
  • Arch Pharmalabs
  • Asana BioSciences
  • Ash Stevens
  • Aspyrian Therapeutics
  • Astellas Pharma
  • AstraZeneca
  • Asymchem
  • AURA Biotechnologies
  • AutekBio
  • Avanthera
  • Avid Bioservices
  • Batavia Biosciences
  • Baxter BioPharma Solutions
  • Bayer HealthCare
  • BerGenBio
  • Bharat Serums and Vaccines
  • BIBITEC
  • BINEX
  • Bio-Synthesis
  • BioAgilytix
  • BioConnection
  • Biomatik
  • BioMed Valley Discoveries
  • Biosynergy
  • BioTechLogic
  • BioTechnique
  • Biotechpharma
  • Biotecnol
  • Biotest
  • BioVectra
  • Biovian
  • BlinkBio
  • Bliss Biopharmaceutical
  • Boehringer Ingelheim BioXcellence
  • Bristol-Myers Squibb
  • Bryllan
  • BSP Pharmaceuticals
  • Cambrex
  • Cambridge Major Laboratories
  • Capsugel
  • CARBOGEN AMCIS
  • Catalent Pharma Solutions
  • Cedarburg Pharmaceuticals
  • Celgene
  • Cell Culture Company
  • Cell Essentials
  • Cellerant Therapeutics
  • CellMosaic
  • Celltrion
  • Celon Laboratories
  • Celonic
  • Centrose
  • Cerbios-Pharma
  • Charles River Laboratories
  • ChemCon
  • ChemPartner
  • ChemSun Pharmaceutical
  • Chiome Bioscience
  • Chugai Pharmaceutical
  • CinnaGen
  • CMC Biologics
  • Cobra Biologics
  • Coldstream Laboratories
  • Compugen
  • Concortis Biotherapeutics
  • Cook Pharmica
  • CordenPharma
  • Creative Biolabs
  • Crystal Pharma
  • Custom Pharma Services
  • CytomX Therapeutics
  • Cytovance Biologics
  • Daiichi Sankyo
  • Dalton Pharma Services
  • Debiopharm
  • DM Bio
  • Dorizoe Lifesciences
  • Dottikon Exclusive Synthesis
  • DSM Pharmaceuticals
  • EirGen Pharma
  • EirGenix
  • Eli Lilly
  • Emergent BioSolutions
  • Esperance Pharmaceuticals
  • ETH Zurich
  • EuBiologics
  • Evonik
  • Excella
  • Farmabios
  • FineTech Pharmaceuticals
  • Formation Biologics
  • Formex
  • Formosa Laboratories
  • Fortis Therapeutics
  • For‐Robin
  • FOSUN Pharma
  • FUJIFILM Diosynth Biotechnologies
  • Fusion Antibodies
  • Gala Biotech
  • GE Healthcare
  • GEA Pharma Systems
  • Genentech
  • Genmab
  • Genzyme
  • Glenmark Pharmaceuticals
  • Glycotope Biotechnology
  • Glythera
  • Goodwin Biotechnology
  • GP Pharm
  • Grand River Aseptic Manufacturing
  • Green Cross
  • Groningen Research Institute of Pharmacy
  • GSK
  • GTP Technology
  • HALIX
  • Halozyme
  • Hangzhou DAC Biotech
  • Haupt Pharma
  • Heidelberg Pharma
  • Helsinn Advanced Synthesis
  • Heraeus Deutschland
  • Hetero
  • Hong Kong Institute of Biotechnology
  • Hospira One2One
  • ICROM
  • Idifarma
  • IDT Australia
  • IDT Biologika
  • Igenica Biotherapeutics
  • ImmunoGen
  • Immunomedics
  • Indena
  • Innate Pharma
  • Inno Biologics
  • Innovation Center for Immune Therapy,  Tsinghua University
  • Intas Pharmaceuticals
  • Integrity Bio
  • Intellect Neurosciences
  • IRIX Pharmaceuticals
  • JHL Biotech
  • Johns Hopkins University
  • Johnson Matthey
  • Kamat Pharmatech
  • KBI Biopharma
  • Kemwell Biopharma
  • Kyongbo Pharmaceutical
  • Kyowa Hakko Kirin
  • Labochim
  • Laboratorios Normon
  • LAMPIRE Biological Laboratories
  • LegoChem Biosciences
  • Leica Biosystems
  • Levena Biopharma
  • LFB Biomanufacturing
  • LinXis
  • Lonza
  • MAB Discovery
  • MabPlex
  • MabVax Therapeutics
  • MacroGenics
  • Maine Biotechnology Services
  • MassBiologics
  • Medichem
  • MedImmune
  • Meditope Biosciences
  • Medix Biochemica
  • Menarini Group
  • Merck (SAFC)
  • Meridian Life Science
  • Merrimack Pharmaceuticals
  • Mersana Therapeutics
  • Metrics Contract Services
  • Millennium Pharmaceuticals
  • MINAKEM High Potent
  • Mitsubishi Tanabe Pharma
  • Molecular and Cellular Therapeutics, University of Minnesota
  • Morphotek
  • MuseChem
  • Mycenax Biotech
  • NanoValent Pharmaceuticals
  • National Cancer Institute
  • National Research Council Canada
  • NBE Therapeutics
  • NerPharma
  • Nitto Avecia Pharma Services
  • Nordic Nanovector
  • Nova Laboratories
  • Novartis
  • Novasep
  • OBI Pharma
  • OctoPlus
  • Olon
  • OmniChem
  • Oncotec Pharma Produktion
  • OsoBio
  • Oxford BioTherapeutics
  • Panacea Biotec
  • Paragon Bioservices
  • Particle Sciences
  • Patheon
  • Penn Pharma
  • Pfanstiehl
  • Pfizer
  • Pharmaceutics International
  • PharmaMar
  • Pharmatek
  • Pharmedartis
  • Philochem
  • Philogen
  • Pierre Fabre
  • Piramal Pharma Solutions
  • Polymun Scientific
  • PrasFarma
  • Praxis Pharmaceutical
  • Precision Antibody
  • PREMAS Biotech
  • ProBioGen
  • Procos
  • ProJect Pharmaceutics
  • ProMab Biotechnologies
  • PX'Therapeutics
  • Quotient Sciences
  • Recipharm
  • Redwood Bioscience
  • Regeneron Pharmaceuticals
  • Regis Technologies
  • Reliance Life Sciences
  • RemeGen
  • Rentschler Biopharma
  • Research Corporation Technologies
  • Richter-Helm BioLogics
  • Roche
  • Rottendorf Pharma
  • Saltigo
  • Samsung Medical Center
  • Sandoz
  • Sanofi
  • Sartorius Stedim Biotech
  • ScinoPharm
  • Seasun Biomaterials
  • Seattle Genetics
  • Shenogen
  • Siegfried
  • Sorrento Therapeutics
  • Spirogen
  • STA Pharmaceutical
  • Stason Pharmaceuticals
  • Stemcentrx
  • Sutro Biopharma
  • Symbiosis Pharmaceutical Services
  • Symphogen
  • Synaffix
  • Syndivia
  • Syngene
  • Syntagon
  • Synthon
  • Synthorx
  • Takara Bio
  • Takeda Oncology
  • TAPI
  • TBD-Biodiscovery
  • Telix Pharmaceuticals
  • The Chemistry Research Solution
  • The Scripps Research Institute
  • Theranyx
  • Therapure Biopharma
  • Thermo Fisher Scientific
  • Toyobo Biologics
  • Transporin
  • TranXenoGen
  • Triphase Accelerator
  • Tube Pharma
  • Uman Pharma
  • University of Bonn
  • University of California
  • University of Georgia
  • UPM Pharmaceuticals
  • Uquifa
  • Vaccinex
  • Vetter Pharma
  • Vista Biologicals
  • Visterra
  • VUAB Pharma
  • Waisman Biomanufacturing
  • Weill Cornell Medicine
  • Wolfe Laboratories
  • WuXi Biologics
  • Xintela
  • Yale School of Medicine
  • Zymeworks
Note: Product cover images may vary from those shown
6 of 5
Note: Product cover images may vary from those shown
Adroll
adroll